Study on the relationship between tumor specificity and neoadjuvant therapy in locally advanced rectal cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055737

Enrollment

Unknown

Registered

2022-01-17

Start date

2022-05-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

Patients diagnosed as colorectal cancer:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are diagnosed as colorectal cancer and planning to receive neoadjuvant therapy from January 2022 to December 2024; 2. Patients who are receiving endoscopic biopsy and having pathological diagnosis; 3. Patients undergoing radical or palliative tumor resection.

Exclusion criteria

Exclusion criteria: 1. Patients with other inflammatory bowel diseases, such as inflammatory bowel disease; 2. FAP patients.

Design outcomes

Primary

Measure	Time frame
Tumor regression grade;RNA-seq;Whole Exome Sequencing;	—

Countries

China

Contacts

Public ContactYu Zhaoliang

The Sixth Affiliated Hospital, Sun Yat-Sen University

823788727@qq.com+86 15902054412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026